Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
Taiwan · Delayed Price · Currency is TWD 137.50
+0.50 (0.36%)
Sep 8, 2026, 12:29 PM CST
TPEX:3218 Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,607 | 12,370 | 16,945 | 23,469 | 23,859 | 21,543 | |
Market Cap Growth | -23.03% | -27.00% | -27.80% | -1.64% | 10.75% | 18.41% |
Enterprise Value | 12,116 | 11,792 | 16,391 | 23,062 | 23,751 | 21,599 |
Last Close Price | 137.00 | 137.83 | 182.60 | 246.09 | 246.00 | 217.97 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 10.18 | 11.86 | 15.92 | 22.46 | 28.05 | 36.18 |
Forward PE | 9.89 | 10.66 | 15.24 | 19.41 | 24.67 | 27.75 |
PS Ratio | 2.72 | 2.94 | 4.01 | 5.75 | 6.83 | 8.19 |
PB Ratio | 2.97 | 2.97 | 4.51 | 7.02 | 8.43 | 9.25 |
P/TBV Ratio | 3.00 | 3.08 | 4.71 | 7.44 | 9.04 | 9.97 |
P/FCF Ratio | 8.88 | 11.21 | 13.69 | 21.71 | 30.65 | 36.68 |
P/OCF Ratio | 6.53 | 7.42 | 10.13 | 15.11 | 18.81 | 23.63 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.83 | 2.81 | 3.88 | 5.65 | 6.80 | 8.21 |
EV/EBITDA Ratio | 6.38 | 6.82 | 9.43 | 14.49 | 18.34 | 22.91 |
EV/EBIT Ratio | 9.07 | 8.54 | 11.73 | 17.58 | 21.97 | 28.10 |
EV/FCF Ratio | 9.27 | 10.68 | 13.25 | 21.33 | 30.51 | 36.77 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.39 | 0.26 | 0.28 | 0.23 | 0.28 | 0.33 |
Debt / EBITDA Ratio | 0.79 | 0.55 | 0.55 | 0.44 | 0.54 | 0.71 |
Debt / FCF Ratio | 1.15 | 0.96 | 0.85 | 0.72 | 1.01 | 1.31 |
Net Debt / Equity Ratio | 0.12 | -0.25 | -0.23 | -0.26 | -0.17 | -0.12 |
Net Debt / EBITDA Ratio | 0.28 | -0.60 | -0.50 | -0.54 | -0.38 | -0.29 |
Net Debt / FCF Ratio | 0.37 | -0.94 | -0.70 | -0.80 | -0.64 | -0.46 |
Asset Turnover | 0.71 | 0.71 | 0.78 | 0.85 | 0.85 | 0.76 |
Inventory Turnover | 5.82 | 5.80 | 5.80 | 6.26 | 7.89 | 11.17 |
Quick Ratio | 1.10 | 2.55 | 2.29 | 2.18 | 2.05 | 2.17 |
Current Ratio | 1.36 | 2.92 | 2.61 | 2.52 | 2.37 | 2.43 |
Return on Equity (ROE) | 31.24% | 26.65% | 29.59% | 34.48% | 33.66% | 27.96% |
Return on Assets (ROA) | 13.81% | 14.55% | 16.04% | 17.02% | 16.37% | 13.88% |
Return on Invested Capital (ROIC) | 31.61% | 35.99% | 41.46% | 43.98% | 39.16% | 33.87% |
Return on Capital Employed (ROCE) | 26.70% | 27.30% | 29.90% | 31.90% | 30.10% | 25.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 9.86% | 8.43% | 6.28% | 4.45% | 3.56% | 2.76% |
FCF Yield | 11.26% | 8.92% | 7.30% | 4.61% | 3.26% | 2.73% |
Dividend Yield | 5.62% | 5.62% | 4.11% | 2.84% | 2.30% | 2.06% |
Payout Ratio | 57.36% | 60.95% | 55.70% | 45.89% | 44.75% | 53.70% |
Buyback Yield / Dilution | -0.15% | -0.10% | -0.08% | -0.04% | -0.03% | 0.03% |
Total Shareholder Return | 5.46% | 5.53% | 4.03% | 2.80% | 2.27% | 2.10% |